Aurigene (a wholly owned subsidiary of Dr. Reddy’s Laboratories) is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) with over two decades of experience in drug discovery and development. Aurigene’ s mission is to accelerate the development and delivery of innovative medicines to patients through an efficient drug discovery process. In alignment with this mission, Aurigene added the following tools to its service offerings:
- Computer Aided Drug Design (CADD) & Bioinformatics: A unique blend of traditional CADD, physics-based simulation, and bioinformatics applications
- Aurigene.AI: An AI-assisted drug discovery platform
- Aurimine: A virtual database comprising over 12 billion compounds
These innovations reinforce Aurigene’ s commitment to advancing drug discovery and bringing innovative medicines to realization.
Aurigene.AI features a meticulously curated compound database validated with structure normalization rules, continuously expanding using both in-house and public domain information. This robust database—currently containing 180 million compounds and 1.6 million validated bioassay data points—serves as a powerful search engine and training ground for AI algorithms. It is searchable via structure, property, or semantic queries to extract relevant information for specific purposes.
Aurigene.AI also allows extensive customization by incorporating multiple AI models into a single interface. It serves as a one-stop shop for a wide variety of top-tier predictive and generative AI models, alongside computational and CADD models. As of now, the platform includes 11 generative AI models, 4 predictive AI models, and 8 computational/CADD models. This modular and embedded design enables Aurigene’ s scientific experts to cherry-pick the right combination of models for targeted applications.
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。